Robinson Dean M, Scott Lesley J
Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand.
Drugs. 2005;65(4):559-76. doi: 10.2165/00003495-200565040-00008.
Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US paediatric, patients. Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure. In well designed clinical trials, paricalcitol was as effective as calcitriol and as well tolerated in terms of the incidence of prolonged hypercalcaemia and/or elevated calcium-phosphorus product (Ca x P). Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure.
帕立骨化醇（泽迈）是一种合成的维生素D2类似物，通过与维生素D受体结合来抑制甲状旁腺激素（PTH）的分泌。它在美国和大多数欧洲国家被批准用于静脉注射，以预防和治疗成人及美国儿科患者中与慢性肾衰竭相关的继发性甲状旁腺功能亢进。帕立骨化醇能有效降低血清PTH水平升高，并且在患有与慢性肾衰竭相关的继发性甲状旁腺功能亢进的儿童和成人中通常耐受性良好。在精心设计的临床试验中，就高钙血症持续时间和/或钙磷乘积（Ca×P）升高的发生率而言，帕立骨化醇与骨化三醇效果相当且耐受性良好。因此，帕立骨化醇是治疗成人和儿童慢性肾衰竭继发性甲状旁腺功能亢进的一个有用选择。
